Aura Biosciences, Inc.
US ˙ NasdaqGM ˙ US05153U1079

SecurityAURA / Aura Biosciences, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership558,158 shares
Latest Disclosed Value $ 3,731,852
Dimensional Fund Advisors Lp reports 7.77% increase in ownership of AURA / Aura Biosciences, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 558,158 shares of Aura Biosciences, Inc. (US:AURA) valued at $3,734,077 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 517,916 shares of Aura Biosciences, Inc.. This represents a change in shares of 7.77% during the quarter. The current value of the position is $3,700,588 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F AURA BIOSCIENCES COM 05153U107 558,158 40,242 7.77 3,732 32.21 0.0002
2026-02-12 2025-12-31 13F AURA BIOSCIENCES COM 05153U107 517,916 20,641 4.15 2,823 -8.17 0.0006
2025-11-12 2025-09-30 13F AURA BIOSCIENCES COM 05153U107 497,275 41,118 9.01 3,073 7.64 0.0007
2025-08-12 2025-06-30 13F AURA BIOSCIENCES COM 05153U107 456,157 50,231 12.37 2,856 19.96 0.0007
2025-05-13 2025-03-31 13F AURA BIOSCIENCES COM 05153U107 405,926 40,102 10.96 2,380 -20.83 0.0006
2025-02-13 2024-12-31 13F AURA BIOSCIENCES COM 05153U107 365,824 73,062 24.96 3,007 15.26 0.0007
2024-11-07 2024-09-30 13F AURA BIOSCIENCES COM 05153U107 292,762 42,387 16.93 2,609 37.84 0.0006
2024-08-09 2024-06-30 13F AURA BIOSCIENCES COM 05153U107 250,375 41,711 19.99 1,892 15.51 0.0005
2024-05-10 2024-03-31 13F AURA BIOSCIENCES COM 05153U107 208,664 30,946 17.41 1,638 4.00 0.0004
2024-02-07 2023-12-31 13F AURA BIOSCIENCES COM 05153U107 177,718 66,178 59.33 1,575 57.50 0.0005
2023-11-09 2023-09-30 13F AURA BIOSCIENCES COM 05153U107 111,540 71,520 178.71 1,001 102.43 0.0003
2023-08-09 2023-06-30 13F AURA BIOSCIENCES COM 05153U107 40,020 40,020 494 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.